Clinical Trial Detail

NCT ID NCT04294576
Title Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors BJ Bioscience, Inc.
Indications

head and neck squamous cell carcinoma

lung non-small cell carcinoma

cholangiocarcinoma

pancreatic cancer

stomach cancer

Advanced Solid Tumor

melanoma

Therapies

BJ-001 + Pembrolizumab

BJ-001

Age Groups: senior adult

No variant requirements are available.